U.S. P2Y12 Inhibitors Market, by Drug (Clopidogrel, Ticlopidine, Ticagrelor, Prasugrel, Cangrelor, and Others), by Route of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Percutaneous Coronary Interventions, Myoca

U.S. P2Y12 Inhibitors Market, by Drug (Clopidogrel, Ticlopidine, Ticagrelor, Prasugrel, Cangrelor, and Others), by Route of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Percutaneous Coronary Interventions, Myocardial Infarction, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

P2Y12 receptor blockers are group of antiplatelet drugs. Antiplatelet are medicines that stop cells in the blood (platelets) from sticking together and forming a clot. A blood clot can lead to a heart attack or stroke. The P2Y12 receptor is a key player in platelet activation and represents an effective pharmacological target for the inhibition of platelet aggregation and prevention of atherothrombotic events. P2Y12 receptor blocker includes clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor drugs
Market Dynamics
Increasing prevalence of cardiovascular disease is expected to drive the market growth during the forecast period. For instance, according to data published in March 2019 by Florida Department of Health, responsible for the regulation of health practitioners for the preservation of the health, safety, and welfare of the public, stated that heart disease accounts for about two out of 10 deaths in Florida. Moreover, there were 80,402 coronary heart disease hospitalizations (including both angina and myocardial infarction) or an average of 220 coronary heart disease hospitalizations each day in 2018. Increasing government initiative to spread awareness regarding cardiovascular diseases is expected to drive the market growth over the forecast period. For instance, Million Hearts 2022, a national initiative co-led by Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services to prevent one million heart attacks and strokes in five years. Moreover, the initiative focuses partner actions on a small set of priorities selected for their impact on heart disease, stroke, and related conditions.
Key features of the study:
This report provides in-depth analysis of the U.S. P2Y12 inhibitors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. P2Y12 inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. P2Y12 inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. P2Y12 inhibitors market
Detailed Segmentation:
U.S. P2Y12 Inhibitors Market, By Drug :
Clopidogrel
Ticlopidine
Ticlopidine
Prasugrel
Cangrelor
Others
U.S. P2Y12 Inhibitors Market, By Route of Administration :
Oral
Intravenous
U.S. P2Y12 Inhibitors Market, By Application :
Angioplasty
Arterial Thrombosis
Percutaneous Coronary Interventions
Myocardial Infarction
Others
U.S. P2Y12 Inhibitors Market, By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Mylan N.V.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Bristol-Myers Squibb
Dr Reddy's Laboratories
Teva Pharmaceuticals USA, Inc.
AstraZeneca
Genentech
Eli Lilly and Company
Panacea Biotec
CHIESI USA, Inc.
Lupin
Cipla
Biocon
“*” marked represents similar segmentation in other categories in the respective section.